• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
Kezar Life Sciences, Inc. (KZR) Stock Price, News & Analysis

Kezar Life Sciences, Inc. (KZR) Stock Price, News & Analysis

Currency in USD Disclaimer

$7.50

-$0.12

(-1.57%)

Day's range
$7.41
Day's range
$7.6
50-day range
$5.2
Day's range
$91.8
  • Country: US
  • ISIN: US49372L1008
52 wk range
$5.2
Day's range
$11.4
  • CEO: Dr. Christopher J. Kirk Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -3.37
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (KZR)
  • Company Kezar Life Sciences, Inc.
  • Price $7.50
  • Changes Percentage (-1.57%)
  • Change -$0.12
  • Day Low $7.41
  • Day High $7.60
  • Year High $11.40

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/13/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $17.50
  • High Stock Price Target $21.00
  • Low Stock Price Target $14.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.39
  • Trailing P/E Ratio -0.49
  • Forward P/E Ratio -0.49
  • P/E Growth -0.49
  • Net Income $-101,870,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Kezar Life Sciences, Inc. Frequently Asked Questions

  • What were the earnings of KZR in the last quarter?

    In the last quarter Kezar Life Sciences, Inc. earnings were on Tuesday, November, 12th. The Kezar Life Sciences, Inc. maker reported -$2.78 EPS for the quarter, beating analysts' consensus estimates of -$3.03 by $0.25.

  • What is the Kezar Life Sciences, Inc. stock price today?

    Today's price of Kezar Life Sciences, Inc. is $7.50 — it has decreased by -1.57% in the past 24 hours. Watch Kezar Life Sciences, Inc. stock price performance more closely on the chart.

  • Does Kezar Life Sciences, Inc. release reports?

    Yes, you can track Kezar Life Sciences, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Kezar Life Sciences, Inc. stock forecast?

    Watch the Kezar Life Sciences, Inc. chart and read a more detailed Kezar Life Sciences, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Kezar Life Sciences, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Kezar Life Sciences, Inc. stock ticker.

  • How to buy Kezar Life Sciences, Inc. stocks?

    Like other stocks, KZR shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Kezar Life Sciences, Inc.'s EBITDA?

    Kezar Life Sciences, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Kezar Life Sciences, Inc.’s financial statements.

  • What is the Kezar Life Sciences, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -14.5528571429, which equates to approximately -1,455.29%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Kezar Life Sciences, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Kezar Life Sciences, Inc.'s financials relevant news, and technical analysis. Kezar Life Sciences, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Kezar Life Sciences, Inc. stock currently indicates a “sell” signal. For more insights, review Kezar Life Sciences, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.